Skip to main content

NERVGEN PHARMA CORP.

corporate_fare Company Profile

NERVGEN PHARMA CORP.

NGEN·NASDAQ·Life Sciences·CIK 0001751912

NervGen Pharma Corp. is a biotechnology company focused on discovering, developing, and commercializing pharmaceutical treatments to repair the nervous system following neurotrauma and neurologic disease. The company's primary product candidate is NVG-291, which is currently in a Phase 1b/2a clinical trial. This trial is evaluating NVG-291 for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease. Another product candidate, NVG-300, is in preclinical studies for ischemic stroke, amyotrophic lateral sclerosis, and a confirmatory SCI study. NervGen Pharma Corp. holds a licensing agreement with Case Western Reserve University, granting it rights to develop and commercialize a patented technology that shows therapeutic potential for spinal cord injury and other conditions involving nerve damage. The company was incorporated in 2017 and operates from its headquarters in Vancouver, Canada.

NERVGEN PHARMA CORP. (NASDAQ:NGEN) is a publicly traded company in the Life Sciences sector. Wiseek monitors NGEN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • NervGen Reports Strong Phase 1b/2a Gait Analysis Data for NVG-291, Showing Neural Recovery
  • NervGen Pharma Increases Shelf Offering Capacity to $250 Million Amidst Going Concern Warning
  • NervGen's NVG-291 Demonstrates Genuine Neural Recovery in Spinal Cord Injury Study
  • NervGen Pharma Prices $60M Public Offering at Premium to Market, Securing Critical Funding
  • NervGen Prices $60M Public Offering at $2.50/Share, Securing Critical Funding

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$44.12M
Diluted EPS
-$0.61
Op. Cash Flow
-$19.5M
Cash & Equivalents
$22.07M
Debt / Equity
0.00×
Shares Outstanding
79.65M sh
Source: 40-F · filed 2026-03-31 · accession 0001104659-26-037357

Insider Transactions

NGEN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with N →
$1.91 +0.02% today
52-week range · as of 2026-05-26 $1.98 – $6.3
Market cap
$152.96M
Volume
1.3M (1.1× avg)
3-mo avg 1.1M
Live data · 2026-06-12 02:05 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed NGEN - Latest Insights

NGEN
May 26, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.16
Real-time Price: $1.91 info
Change: -$0.2499 (-12%) info
Market Cap: $152.959M info
NGEN
May 26, 2026, 9:26 AM EDT
Filing Type: F-10
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $1.91 info
Change: -$0.3005 (-14%) info
Market Cap: $152.959M info
NGEN
May 26, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $1.91 info
Change: -$0.2605 (-12%) info
Market Cap: $152.959M info
NGEN
May 22, 2026, 5:24 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.09
Real-time Price: $1.91 info
Change: -$0.1808 (-9%) info
Market Cap: $152.959M info
NGEN
May 21, 2026, 11:28 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.81
Real-time Price: $1.91 info
Change: -$0.8955 (-32%) info
Market Cap: $152.959M info
NGEN
May 21, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.91 info
Change: -$1.05 (-35%) info
Market Cap: $152.959M info
NGEN
May 18, 2026, 4:19 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.64
Real-time Price: $1.91 info
Change: -$1.73 (-48%) info
Market Cap: $152.959M info
NGEN
May 15, 2026, 4:28 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.57
Real-time Price: $1.91 info
Change: -$1.66 (-46%) info
Market Cap: $152.959M info
NGEN
Apr 27, 2026, 5:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $1.91 info
Change: -$2.07 (-52%) info
Market Cap: $152.959M info
NGEN
Apr 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $1.91 info
Change: -$2.23 (-54%) info
Market Cap: $152.959M info
NGEN
Apr 07, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.45
Real-time Price: $1.91 info
Change: -$2.54 (-57%) info
Market Cap: $152.959M info
NGEN
Mar 31, 2026, 7:30 AM EDT
Filing Type: 40-F
Importance Score:
9
Price at Filing: $3.64
Real-time Price: $1.91 info
Change: -$1.73 (-48%) info
Market Cap: $152.959M info
NGEN
Mar 13, 2026, 5:04 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $1.91 info
Change: -$1.69 (-47%) info
Market Cap: $152.959M info
NGEN
Feb 13, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.17
Real-time Price: $1.91 info
Change: -$2.26 (-54%) info
Market Cap: $152.959M info
NGEN
Feb 10, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.10
Real-time Price: $1.91 info
Change: -$2.19 (-53%) info
Market Cap: $152.959M info
NGEN
Jan 08, 2026, 4:09 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.90
Real-time Price: $1.91 info
Change: -$3.99 (-68%) info
Market Cap: $152.959M info